In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO

, , Comments Off on In for the China biotech gold rush, BeiGene eyes monster $800M-plus Hong Kong IPO

Fast on the heels of Ascletis’ record $400 million raise on the Hong Kong stock exchange, BeiGene is proposing its own IPO in the city — to run parallel with its current listing on Nasdaq. And they ar…
( read original story …)